Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_226_библиотеки_им_акад_М_И_Перельмана
.pdf
111
83. Burden of liver diseases in the world / S. K. Asrani, H. Devarbhavi, J.
Eaton, P. S. Kamath // Journal of hepatology. 2019. P. 151171.
84. Cellular crosstalk mediated by platelet-derived growth factor BB and
transforming growth factor during hepatic injury activates hepatic stellate cells / S.
Mekala, S. V. Tulimilli, R. Geesala [et al.] // Canadian journal of physiology and
pharmacology. 2018. P. 728741.
85. Cholankeril, G. Alcoholic liver disease replaces hepatitis C virus infection
as the leading indication for liver transplantation in the United States / G. Cholankeril,
A. Ahmed // Clinical gastroenterology and hepatology. 2018. P.
13561358.
86. Comorbidities and nonalcoholic fatty liver disease: the chicken, the egg, or
both? / L. M. Glass, C. M. Hunt, M. Fuchs, G. L. Su // Federal practitioner. 2019.
P. 6471.
87. Comparison of the ability of Child-Pugh score, MELD score, and ICG-R15
to assess preoperative hepatic functional reserve in patients with hepatocellular
carcinoma / Y.-Y. Wang, X.-H. Zhao, L. Ma [et al.] // Journal of surgical oncology.
2018. P. 440445.
88. Concordance in a world without a gold standard: a new non-invasive
methodology for improving accuracy of fibrosis markers / T. Poynard, P. Ingiliz, L.
Elkrief [et al.] // PloS one. 2008. Vol. 3, 12. P. e3857.
89. Continuous
13
C-methacetin breath test differentiates biliary atresia from
other causes of neonatal cholestasis / E. Shteyer, G. Lalazar, N. Hemed [et al.] // Journal
of pediatric gastroenterology and nutrition. 2013. P. 6065.
90. Contribution of resident stem cells to liver and biliary tree regeneration in
human diseases / D. Overi, G. Carpino, V. Cardinale [et al.] // International journal of
molecular sciences. 2018. Article 2917.
91. Correlation of NT-proBNP with metabolic liver function as assessed with
13
C-methacetin breath test in patients with acute decompensated heart failure / M.
https://t.me/med1917
112
Hendrich
2010. P. 321322.
92. Correlation of the functional liver mass with left ventricular ejection
fraction and left atrial diameter in patients with congestive heart
2008. Vol.
P. 271273.
93. Critical appraisal of
13
C breath tests for microsomal liver function:
aminopyrine revisited / K. E. Pijls, H. de Vries, S. Nikkessen [et al.] // Liver
international. 2014. P. 487494.
94. Decreased metabolism of
13
C-caffeine via hepatic CYP
1
A
2
in marasmus
and kwashiorkor based on breath test / K. A. Oshikoya, K. Smith, H. Sammons, I.
Choonara // Journal of basic and clinical physiology and pharmacology. 2015. Vol.
P. 105113.
95. Dienstag, J. L. The role of liver biopsy in chronic hepatitis C / J. L.
Dienstag // Hepatology. 2002. P. S152S160.
96. EASL Clinical Practical Guidelines on the management of acute
(fulminant) liver failure / European Association for the Study of the Liver, Clinical
practice guidelines panel // Journal of hepatology. 2017. P. 1047
1081.
97. EASL Clinical Practice Guidelines for the management of patients with
decompensated cirrhosis / European Association for the Study of the Liver // Journal of
hepatology. 2018. P. 406460.
98. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for
evaluation of liver disease severity and prognosis / European Association for Study of
Liver, Asociacion Latinoamericana para el Estudio del Higado // Journal of hepatology.
2015. Vol. 63, 1. P. 237264.
99. EASL-EASD-EASO Clinical Practice Guidelines for the management of
non-alcoholic fatty liver disease / European Association for the Study of the Liver
(EASL), European Association for the Study of Diabetes (EASD), European
https://t.me/med1917
113
Association for the Study of Obesity (EASO) // Obesity facts. 2016. Vol. 9.
P. 6590.
100. Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with
genotype-1 and-3 HCV infection: results from a Russian Phase IIIb study / V.
Isakov, K. Zhdanov, K. Kersey
[et al.] // Antiviral therapy. 2016. P.
671678.
101. Endotoxin metabolism reflects hepatic functional reserve in end-stage liver
disease / N. Okada, Y. Sanada, T. Urahashi [et al.] // Transplantation proceedings.
2018. P. 13601364.
102. Evaluation of percutaneous liver biopsy complications in patients with
chronic viral hepatitis / S. Kose, G. Ersan, B. Tatar
[et al.] // The Eurasian journal of
medicine. 2015. P. 161164.
103. Evaluation of the
13
C-methacetin breath test for quantitative liver function
testing / S. Klatt, C. Taut, D. Mayer [et al.] // Zeitschrift fur Gastroenterologie. 1997.
P. 609614.
104. FibroTest FibroSURE: towards a universal biomarker of liver fibrosis? /
T. Poynard, F. Imbert-Bismut, M. Munteanu, V. Ratziu // Expert review of molecular
diagnostics. 2005. P. 1521.
105. From NAFLD to NASH to cirrhosis new insights into disease
mechanisms / A. Wree, L. Broderick, A. Canbay [et al.] // Nature reviews.
Gastroenterology & hepatology. 2013. P. 627636.
106. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic
assessment of prevalence, incidence, and outcomes / Z. M. Younossi, A. B. Koenig. D.
Abdelatif [et al.] // Hepatology. 2016. P. 7384.
107. Global hepatitis report 2017 / World Health Organization. Geneva :
World Health Organization, 2017. 83 p.
108. Global status report on alcohol and health 2018. Text : electronic //
World Health Organization : website. 2018. 27 September. URL:
https://t.me/med1917
114
https://www.who.int/substance_abuse/publications/global_alcohol_report/en/ (date of
request: 21.02.2021).
109. Global, regional, and national incidence, prevalence, and years lived with
disability for 328 diseases and injuries for 195 countries, 19902016: a systematic
analysis for the Global Burden of Disease Study 2016 / T. Vos, A. A. Abajobir, K. H.
Abate [et al.] // Lancet. 2017. P. 12111259.
110. Gorowska-Kowolik, K.
13
C methacetin breath test for assessment of
microsomal liver function: methodology and clinical application / K. Gorowska-
Kowolik, A. Chobot, J. Kwiecien // Gastroenterology research and practice. 2017.
Vol. 2017, Article ID 7397840.
111. Halle, B. M. Indocyanine green plasma disappearance rate as dynamic liver
function test in critically ill patients / B. M. Halle, T. D. Poulsen, H. P. Pedersen // Acta
anaesthesiologica Scandinavica. 2014. P. 12141219.
112. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current
knowledge and implications for management / G. Cholankeril, R. Patel, S. Khurana, S.
K. Satapathy // World journal of hepatology. 2017. P. 533543.
113. High mortality rates for SARS-CoV-2 infection in patients with pre-
existing chronic liver disease and cirrhosis: Preliminary results from an international
registry / A. M. Moon, G. J. Webb, C. Aloman [et al.] // Journal of hepatology. 2020.
P. 705708.
114. How often do our liver core biopsies reach current definitions of adequacy?
/ E. Fryer, L. M. Wang, C. Verrill, K. Fleming // Journal of clinical pathology. 2013.
P. 10871089.
115. IL-4 receptor alpha signaling through macrophages differentially regulates
liver fibrosis progression and reversal / S.-Y. Weng, X. Wang, S. Vijayan [et al.] //
EBioMedicine. 2018. Vol. 29. P. 92103.
116. In vivo research with stable isotopes in biochemistry, nutrition and clinical
medicine: an overview / K. de Meer, M. J. Roef, W. Kulik, C. Jakobs // Isotopes in
environmental and health studies. 1999. -2. P. 1937.
https://t.me/med1917
115
117. Indocyanine green clearance test combined with MELD score in predicting
the short-term prognosis of patients with acute liver failure / H.-L. Feng, Q. Li, L. Wang
[et al.] // Hepatobiliary & pancreatic diseases international. 2014. P.
271275.
118. Indocyanine green plasma disappearance rate: a new tool for the
classification of paediatric patients with acute liver failure / J. Quintero, M. Miserachs,
J. Ortega [et al.] // Liver international. 2014. P. 689694.
119. Inhibition of notch signaling pathway prevents cholestatic liver fibrosis by
decreasing the differentiation of hepatic progenitor cells into cholangiocytes / X. Zhang,
G. Du, Y. Xu [et al.] // Laboratory investigation. 2016. P. 350360.
120. Interpretation of non-invasive breath tests using
13
C-labeled substrates a
preliminary report with
13
C-methacetin / J. F. Lock, P. Taheri, S. Bauer [et al.] //
European journal of medical research. 2009. P. 547550.
121. Key role of liver sinusoidal endothelial cells in liver fibrosis / M. Xu, X.
Wang, Y. Zou, Y. Zhong // Bioscience trends. 2017. P. 163168.
122. Koyama, Y. Liver inflammation and fibrosis / Y. Koyama, D. A. Brenner //
The Journal of clinical investigation. 2017. P. 5564.
123. Lalazar, G. Assessment of liver function in acute or chronic liver disease
by the methacetin breath test: a tool for decision making in clinical hepatology / G.
Lalazar, Y. Ilan // Journal of breath research. 2009. Article ID
047001.
124. Lalazar, G. Point-of-care continuous
13
C-methacetin breath test improves
decision making in acute liver disease: results of a pilot clinical trial / G. Lalazar, T.
Adar, Y. Ilan // World journal of gastroenterology. 2009. P. 966
972.
125. Lim, Y. S. The global impact of hepatic fibrosis and end-stage liver disease
/ Y. S. Lim, W. R. Kim // Clinics in liver disease. 2008. P. 733746.
126. Liver biopsy / D. C. Rockey, S. H. Caldwell, Z. D. Goodman [et al.] //
Hepatology. 2009. Vol. 49, 3. P. 10171044.
https://t.me/med1917
116
127. Liver cirrhosis in Iceland and Sweden: incidence, aetiology and outcomes /
S. A. Gunnarsdottir, R. Olsson, S. Olafsson [et al.] // Scandinavian journal of
gastroenterology. 2009. P. 984993.
128. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a
systematic analysis / A. A. Mokdad, A. D. Lopez, S. Shahraz [et al.] // BMC medicine.
2014. Vol. 12, Article 145.
129. Liver fibrosis, but no other histologic features, is associated with long-term
outcomes of patients with nonalcoholic fatty liver disease / P. Angulo, D. E. Kleiner, S.
Dam-Larsen [et al.] // Gastroenterology. 2015. P. 389397.
130. Long-term outcomes in patients undergoing liver transplantation for
nonalcoholic steatohepatitis-related cirrhosis / C. Bhati, M. O. Idowu, A. J. Sanyal [et
al.] // Transplantation. 2017. P. 18671874.
131. Machado, M. V. Pathogenesis of nonalcoholic steatohepatitis / M. V.
Machado, A. M. Diehl // Gastroenterology. 2016. P. 17691777.
132. Meta-analyses of FibroTest diagnostic value in chronic liver disease / T.
Poynard, R. Morra, P. Halfon [et al.] // BMC gastroenterology. 2007. Vol. 7, Article
40.
133. Modak, A. S. An update on
13
C-Breath Tests: The transition to
acceptability into clinical practice / A. S. Modak // Volatile biomarkers: Non-invasive
diagnosis in physiology and medicine / A. Amann, D. Smith. Oxford : Elsevier, 2013.
Chapter 14. P. 244262.
134. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an
exponential increase in burden of disease / C. Estes, H. Razavi, R. Loomba [et al.] //
Hepatology. 2018. P. 123133.
135. Nalbantoglu, I. L. K. Role of liver biopsy in nonalcoholic fatty liver disease
/ I. L. K. Nalbantoglu, E. M. Brunt // World journal of gastroenterology. 2014. Vol.
20. P. 90269037.
https://t.me/med1917
117
136. Natarajan, V. SECs (Sinusoidal Endothelial Cells), liver microenvironment,
and fibrosis / V. Natarajan, E. N. Harris, S. Kidambi // BioMed research international.
2017. Vol. 2017, Article ID 4097205.
137. Non-invasive evaluation of the liver disease severity in children with
chronic viral hepatitis using FibroTest and ActiTest comparison with
histopathological assessment / M. Pokorska- -
Aniszewska [et al.] // Clinical and experimental hepatology. 2017. P.
187193.
138. Nuclear medicine liver function tests for pregnant women and children. 1.
Breath tests with
14
C-methacetin and
13
C-
Faust [et al.] // European journal of nuclear medicine. 1985. -4. P.
129133.
139. Penz-sterreicher, M. Fibrosis in autoimmune and cholestatic liver disease
/ M. Penz-
2011. P. 245258.
140. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a
multiethnic cohort of patients with type 2 diabetes mellitus / F. Bril, M. J. McPhaul, M.
P. Caulfield [et al.] // Journal of investigative medicine. 2019. P.
303311.
141. Poynard, T. Cost effectiveness of pegylated interferon alpha 2b and
ribavirin combination in chronic hepatitis C / T. Poynard // Gut. 2003.
10. P. 1532.
142. Prospective comparison of transient elastography, Fibrotest, APRI, and
liver biopsy f J.
Vergniol, J. Foucher [et al.] // Gastroenterology. 2005. P. 343350.
143. Regulators of cholangiocyte proliferation / C. Hall, K. Sato, N. Wu [et al.]
// Gene expression. 2017. P. 155171.
https://t.me/med1917
118
144. Reiss, G. Role of liver biopsy in the management of chronic liver disease:
selective rather than routine / G. Reiss, E. B. Keeffe // Reviews in gastroenterological
disorders. 2005. P. 195205.
145. Review article: the gut microbiome as a therapeutic target in the
pathogenesis and treatment of chronic liver disease / C. A. Woodhouse, V. C. Patel, A.
Singanayagam, D. L. Shawcross // Alimentary pharmacology & therapeutics. 2018.
P. 192202.
146. Robinson, A. J. Applications and limitations of noninvasive methods for
evaluating hepatic fibrosis in patients with nonalcoholic fatty liver disease / A. J.
Robinson, R. J. Won // Clinical liver disease. 2020. P. 157161.
147. Role of
13
C methacetin breath test for non-invasive staging of liver fibrosis
in patients with chronic hepatitis C / C. Fierbinteanu-Braticevici, R. Papacocea, L.
Tribus, B. Cristian // The Indian journal of medical research. 2014.
P. 123129.
148. Role of hepatic resident and infiltrating macrophages in liver repair after
acute injury / Q. You, M. Holt, H. Yin [et al.] // Biochemical pharmacology. 2013.
P. 836843.
149. Rowe, I. A. Lessons from epidemiology: the burden of liver disease / I. A.
Rowe // Digestive diseases. 2017. Vol. 35, 4. P. 304309.
150. Schmidt, L. E. Galactose elimination capacity as a prognostic marker in
patients with severe acetaminophen-
Schmidt, P. Ott, N. Tygstrup // Clinical gastroenterology and hepatology. 2004. Vol.
P. 418424.
151. Schuppan, D. Liver cirrhosis / D. Schuppan, N. H. Afdhal // Lancet.
2008. P. 838851.
152. Schuppan, D. Liver fibrosis: Common mechanisms and antifibrotic
therapies / D. Schuppan // Clinics and research in hepatology and gastroenterology.
2015. Vol. 39, Suppl. 1. P. S51S59.
https://t.me/med1917
119
153. Seki, E. Recent advancement of molecular mechanisms of liver fibrosis / E.
Seki, D. A. Brenner // Journal of hepato-biliary-pancreatic sciences. 2015. Vol. 22,
P. 512518.
154. Sensitivity and specificity of plasma disappearance rate of indocyanine
green as a prognostic indicator in acute liver failure / U. Merle, O. Sieg, W. Stremmel
[et al.] // BMC gastroenterology. 2009. Vol. 9, Article 91.
155. Severe liver disease associated with prolonged exposure to antiretroviral
syndromes. 2006. P. 177182.
156. Stravitz, R. T. Potential use of metabolic breath tests to assess liver disease
and prognosis: has the time arrived for routine use in the clinic? / R. T. Stravitz, Y. Ilan
// Liver international. 2017. P. 328336.
157. Suha, A. A. Analysis of breath allows for non-invasive identification and
quantification of diseases and metabolic dysfunction : ddc-
-
Berlin, 2015. 247 p.
158. Sumida, Y. Limitations of liver biopsy and non-invasive diagnostic tests
for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis / Y.
Sumida, A. Nakajima, Y. Itoh // World journal of gastroenterology. 2014. Vol. 20,
P. 475485.
159. Surgery and hepatocellular carcinoma / N. Akamatsu, U. Cillo, A.
Cucchetti [et al.] // Liver cancer. 2017. P. 4450.
160. Targeting oxidative stress for the treatment of liver fibrosis / T.
Luangmonkong, S. Suriguga, H. A. M. Mutsaers [et al.] // Reviews of physiology,
biochemistry and pharmacology. 2018. Vol. 175. P. 71102.
161. TGF--induced hepatocyte lincRNA-p21 contributes to liver fibrosis in
mice / X. Tu, Y. Zhang, X. Zheng [et al.] // Scientific reports. 2017. 1.
P. 2957.
https://t.me/med1917
120
162. The
13
C-methacetin breath test for quantitative noninvasive liver function
analysis with an isotope-specific nondispersive infrared spectrometer in liver cirrhosis /
B. Pfaffenbach, C. Szymanski [et al.] // Deutsche medizinische
Wochenschrift. 1998. P. 14671471.
163. The burden of liver disease in Europe: a review of available
epidemiological data / M. Blachier, H. Leleu, M. Peck-Radosavljevic [et al.] // Journal
of hepatology. 2013. P. 593608.
164. The global burden of liver disease: the major impact of China / F.-S. Wang,
J.-G. Fan, Z. Zhang [et al.] // Hepatology. 2014. P. 20992108.
165. The global burden of viral hepatitis from 1990 to 2013: findings from the
Global Burden of Disease Study 2013 / J. D. Stanaway, A. D. Flaxman, M. Naghav [et
al.] // Lancet. 2016. P. 10811088.
166. The global, regional, and national burden of cirrhosis by cause in 195
countries and territories, 19902017: a systematic analysis for the Global Burden of
Disease Study 2017 / S. G. Sepanlou, S. Safiri, C. Bisignano [et al.] // The Lancet.
Gastroenterology & hepatology. 2020. P. 245 266.
167. The LiMAx test: a new liver function test for predicting postoperative
outcome in liver surgery / M. Stockmann, J. F. Lock, M. Malinowski [ et al.] // HPB :
the official journal of the International Hepato Pancreato Biliary Association. 2010.
P. 139146.
168. Transection of the oesophagus for bleeding oesophageal varices / R. N.
Pugh, I. M. Murray-Lyon, J. L. Dawson [et al.] // The British journal of surgery. 1973.
P. 646649.
169. Tsymmerman, Y. S. Liver fibrosis: pathogenesis, diagnosis, treatment
prospects / Y. S. Tsymmerman // Herald of pancreatic club. 2020. P.
7684.
170. Ultrasonically-guided liver biopsy / S. N. Rasmussen, H. H. Holm, J. K.
Kristensen, H. Barlebo // British medical journal. 1972. P. 500
502.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана